Registration Deadline:
Event Contact:
More Information:
Explore other Industry Opportunities:
Johnson & Johnson is seeking next-generation advancements in neurodegeneration. The company invites innovators worldwide to submit novel strategies or approaches that aim to prevent or limit the progression of neurodegenerative diseases. Research related to Alzheimer's disease or Parkinson's disease is of highest interest, though compelling approaches for ALS and Huntington's disease may also be considered. Selected applicants will have the opportunity to showcase their science in a closed-door poster session with Johnson & Johnson Innovative Medicine's Neuroscience R&D leadership in London on July 13, 2026.
Approaches of interest
- Interventional approaches targeting neuronal and/or glial biology to promote homeostasis and neuroprotective mechanisms disrupted by aging
- Therapeutic interventions to treat dementia, cognitive decline, mood and depression
- All modalities are in scope
Out of scope
- Medical devices
- Prebiotics, probiotics, and nutraceuticals
- Repurposed drugs
Developmental stage of interest: All stages of development from basic research to registration and approval are in scope.
Summaries generated by AI. Please see attached documentation or email Cameron Sargent, CTTC Licensing Officer, for more information.
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.